We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Noninvasive Prenatal Technique Detects Subchromosomal Abnormalities

By LabMedica International staff writers
Posted on 24 Nov 2015
Noninvasive prenatal testing (NIPT) using sequencing of fetal cell-free DNA from maternal plasma has allowed accurate prenatal diagnosis of aneuploidy without requirement of an invasive procedure and this approach has gained increasing clinical acceptance.

A novel technique has been developed that uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.

An international team of scientists including those at the University of California, San Diego School of Medicine (La Jolla, CA, USA) analyzed blood plasma from 1,476 pregnant women with fetal structural abnormalities detected by ultrasound. More...
These women also underwent an invasive diagnostic procedure and conventional fetal DNA analysis. The scientists compared that information to semiconductor sequencing results on circulating fetal DNA obtained from a blood test on the pregnant women at an average gestational age of 24 weeks.

After DNA extraction, a comparative genomic hybridization analysis (aCGH) was performed using Agilent commercial arrays (Agilent Technologies; Santa Clara, CA, USA). To obtain complete sequences of cell-free DNA (cfDNA) fragments, sequencing was performed using an Ion Proton Sequencer (Life Technologies; Carlsbad, CA, USA). The new semiconductor sequencing method detected 69 of 73 (94.5%) abnormalities of a certain size (greater than one million base pairs) detected by the conventional method. According to the investigators, the cost of NIPT with semiconductor sequencing has the potential to be less expensive than the conventional, invasive prenatal testing method, especially as genetic sequencing technologies continue to decrease in cost.

In the study, semiconductor sequencing detected 55 false positives, of which 35 (63.6%) were due to maternal, rather than fetal, chromosomal abnormalities. That means the new method will require a validation test to screen out maternal abnormalities. NIPT with semiconductor sequencing also needs to be tested at early time points in the pregnancy, at 12 to 16 weeks, and it is hoped to further improve the technique to be able to detect even smaller genetic abnormalities.

The authors concluded that methods they developed can be applied to any mixed biological sample to determine the subchromosomal abnormalities in the minor component, even when this fraction represents only a small percentage of the total DNA. In prenatal diagnostics, samples obtained from chorionic villi could be analyzed for mosaic karyotypes or maternal contamination. The study was published on November 11, 2015 in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

University of California, San Diego School of Medicine
Agilent Technologies 
Life Technologies 



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.